RT Journal Article
SR Electronic
T1 Development and validation of a transcriptional signature for the assessment of fibrosis in organs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.14.20024141
DO 10.1101/2020.03.14.20024141
A1 Bin Wang
A1 Shiju Chen
A1 Hongyan Qian
A1 Rongjuan Chen
A1 Yan He
A1 Xinwei Zhang
A1 Jingxiu Xuan
A1 Yuan Liu
A1 Guixiu Shi
YR 2020
UL http://medrxiv.org/content/early/2020/03/17/2020.03.14.20024141.abstract
AB Background Fibrosis in most organs has proven to be an critical factor related to high risk of morbidity and mortality, but an adequate assessment of fibrosis severity is still challenging. This study tried to evaluate fibrosis severity through a fibrosis transcriptional signature.Methods A fibrosis transcriptional signature was developed through an integrated analysis of multiple expression profiling datasets of human organs with fibrosis-related diseases. A fibrosis severity score for each sample was the calculated through gene set variation analysis (GSVA), and its role in evaluating fibrosis severity was then analyzed.Results Ten expression profiling datasets of human tissues with organ failure were integrated with robust rank aggregation method, and a fibrosis severity score consisting of 149 genes. Most of those included genes were involved in fibrogenic pathways. GSEA analysis revealed that fibrosis transcriptional signature was significantly enriched in the fibrogenic tissues. Additionally, we found that fibrosis transcriptional signature could effectively differentiate fibrosis tissues and non-fibrosis tissues.Conclusion This study developed an useful fibrosis transcriptional signature involved in fibrosis-related diseases. This fibrosis transcriptional signature is helpful in precisely evaluating the fibrosis severity in common organs at the transcriptional level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Natural Science Foundation of China (Grant No. 81971536 and No. U1605223).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript were provioded.